Quantifying the effects of antiangiogenic and chemotherapy drug combinations on drug delivery and treatment efficacy

Tumor-induced angiogenesis leads to the development of leaky tumor vessels devoid of structural and morphological integrity. Due to angiogenesis, elevated interstitial fluid pressure (IFP) and low blood perfusion emerge as common properties of the tumor microenvironment that act as barriers for drug delivery. In order to overcome these barriers, normalization of vasculature is considered to be a viable option. However, insight is needed into the phenomenon of normalization and in which conditions it can realize its promise. In order to explore the effect of microenvironmental conditions and drug scheduling on normalization benefit, we build a mathematical model that incorporates tumor growth, angiogenesis and IFP. We administer various theoretical combinations of antiangiogenic agents and cytotoxic nanoparticles through heterogeneous vasculature that displays a similar morphology to tumor vasculature. We observe differences in drug extravasation that depend on the scheduling of combined therapy; for concurrent therapy, total drug extravasation is increased but in adjuvant therapy, drugs can penetrate into deeper regions of tumor.

[1]  N. Mitsakakis,et al.  Spatial and temporal mapping of heterogeneity in liposome uptake and microvascular distribution in an orthotopic tumor xenograft model. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[2]  M. Uesaka,et al.  Accumulation of sub-100 nm polymeric micelles in poorly permeable tumours depends on size. , 2011, Nature nanotechnology.

[3]  S. McDougall,et al.  Mathematical modelling of dynamic adaptive tumour-induced angiogenesis: clinical implications and therapeutic targeting strategies. , 2006, Journal of theoretical biology.

[4]  D. Ozturk,et al.  Influence of vascular normalization on interstitial flow and delivery of liposomes in tumors , 2015, Physics in medicine and biology.

[5]  Xian Zhou,et al.  RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Christine Allen,et al.  In Vivo Distribution of Polymeric Nanoparticles at the Whole-Body, Tumor, and Cellular Levels , 2010, Pharmaceutical Research.

[7]  D Needham,et al.  Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. , 1993, Cancer research.

[8]  Tracy T Batchelor,et al.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. , 2007, Cancer cell.

[9]  Urszula Ledzewicz,et al.  Optimal and suboptimal protocols for a class of mathematical models of tumor anti-angiogenesis. , 2008, Journal of theoretical biology.

[10]  Arlene Chan,et al.  Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Anthony Fyles,et al.  Interstitial fluid pressure in tumors: therapeutic barrier and biomarker of angiogenesis. , 2008, Future oncology.

[12]  Helen M. Byrne,et al.  A theoretical study of the response of vascular tumours to different types of chemotherapy , 2008, Math. Comput. Model..

[13]  Rakesh K Jain,et al.  Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. , 2012, Cold Spring Harbor perspectives in medicine.

[14]  R. Jain,et al.  TGF-β blockade improves the distribution and efficacy of therapeutics in breast carcinoma by normalizing the tumor stroma , 2012, Proceedings of the National Academy of Sciences.

[15]  M. Ashcroft,et al.  Antiangiogenic Cancer Therapy , 2009, British Journal of Cancer.

[16]  R. Jain,et al.  Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. , 2000, Cancer research.

[17]  R. Jain,et al.  A sensitive in vivo model for quantifying interstitial convective transport of injected macromolecules and nanoparticles. , 2006, Journal of applied physiology.

[18]  H. Schättler,et al.  On optimal delivery of combination therapy for tumors. , 2009, Mathematical biosciences.

[19]  Pu Chen,et al.  Numerical Modeling of Interstitial Fluid Flow Coupled with Blood Flow through a Remodeled Solid Tumor Microvascular Network , 2013, PloS one.

[20]  Efstathios Karathanasis,et al.  Tumor Vascular Permeability to a Nanoprobe Correlates to Tumor-Specific Expression Levels of Angiogenic Markers , 2009, PloS one.

[21]  R K Jain,et al.  Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. , 1990, Cancer research.

[22]  A. Eggermont,et al.  Tumor necrosis factor alpha mediates homogeneous distribution of liposomes in murine melanoma that contributes to a better tumor response. , 2007, Cancer research.

[23]  Robert Gray,et al.  Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R K Jain,et al.  Determinants of tumor blood flow: a review. , 1988, Cancer research.

[25]  I. Tannock,et al.  The intra-tumoral relationship between microcirculation, interstitial fluid pressure and liposome accumulation. , 2015, Journal of controlled release : official journal of the Controlled Release Society.

[26]  Mark A. J. Chaplain,et al.  The effect of interstitial pressure on therapeutic agent transport: coupling with the tumor blood and lymphatic vascular systems. , 2014, Journal of theoretical biology.

[27]  I. Tannock,et al.  Distribution of the anticancer drugs doxorubicin, mitoxantrone and topotecan in tumors and normal tissues , 2013, Cancer Chemotherapy and Pharmacology.

[28]  Theresa M. Allen,et al.  Determination of Doxorubicin Levels in Whole Tumor and Tumor Nuclei in Murine Breast Cancer Tumors , 2005, Clinical Cancer Research.

[29]  Y. Barenholz,et al.  Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. , 1994, Cancer research.

[30]  R. Cardiff,et al.  Longitudinal Investigation of Permeability and Distribution of Macromolecules in Mouse Malignant Transformation Using PET , 2010, Clinical Cancer Research.

[31]  Min Wu,et al.  The effect of interstitial pressure on tumor growth: coupling with the blood and lymphatic vascular systems. , 2013, Journal of theoretical biology.

[32]  Y. Kvinnsland,et al.  Intratumour heterogeneity in the uptake of macromolecular therapeutic agents in human melanoma xenografts , 2003, British Journal of Cancer.

[33]  Jacobus Pfisterer,et al.  A phase 3 trial of bevacizumab in ovarian cancer. , 2011, The New England journal of medicine.

[34]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[35]  Triantafyllos Stylianopoulos,et al.  Combining two strategies to improve perfusion and drug delivery in solid tumors , 2013, Proceedings of the National Academy of Sciences.

[36]  H. I. Freedman,et al.  A mathematical model for the effect of anti-angiogenic therapy in the treatment of cancer tumours by chemotherapy , 2013 .

[37]  Lei Xu,et al.  Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. , 2004, Cancer cell.

[38]  Triantafyllos Stylianopoulos,et al.  Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. , 2011, Annual review of chemical and biomolecular engineering.

[39]  Chi-Hwa Wang,et al.  Simulation of the Delivery of Doxorubicin to Hepatoma , 2001, Pharmaceutical Research.

[40]  I. Tannock,et al.  Repopulation of cancer cells during therapy: an important cause of treatment failure , 2005, Nature Reviews Cancer.

[41]  E. M. Renkin,et al.  Mechanics and thermodynamics of transcapillary exchange , 1984 .

[42]  Rakesh K. Jain,et al.  Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors , 2004, Cancer Research.

[43]  Ricky T. Tong,et al.  Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. , 2007, Cancer research.

[44]  Rakesh K. Jain,et al.  Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases , 2011, Nature Reviews Drug Discovery.

[45]  R. Ramlau,et al.  Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  David J. Waxman,et al.  Combination of antiangiogenesis with chemotherapy for more effective cancer treatment , 2008, Molecular Cancer Therapeutics.

[47]  R. B. Campbell,et al.  Role of tumor–host interactions in interstitial diffusion of macromolecules: Cranial vs. subcutaneous tumors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[48]  S. McDougall,et al.  Mathematical modelling of flow through vascular networks: Implications for tumour-induced angiogenesis and chemotherapy strategies , 2002, Bulletin of mathematical biology.

[49]  F. Kiessling,et al.  Characterizing EPR-mediated passive drug targeting using contrast-enhanced functional ultrasound imaging. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[50]  Florence Hubert,et al.  A new mathematical model for optimizing the combination between antiangiogenic and cytotoxic drugs in oncology , 2012 .

[51]  Heiko Rieger,et al.  Interstitial Fluid Flow and Drug Delivery in Vascularized Tumors: A Computational Model , 2013, PloS one.

[52]  R. Jain,et al.  Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner , 2012, Nature nanotechnology.

[53]  F. Kabbinavar,et al.  Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  Matija Snuderl,et al.  Coevolution of solid stress and interstitial fluid pressure in tumors during progression: implications for vascular collapse. , 2013, Cancer research.

[55]  R. Skalak,et al.  Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery. , 1995, Cancer research.

[56]  Alexander R. A. Anderson,et al.  Mathematical modelling of flow in 2D and 3D vascular networks: Applications to anti-angiogenic and chemotherapeutic drug strategies , 2005, Math. Comput. Model..

[57]  Vladimir P Torchilin,et al.  Barriers to drug delivery in solid tumors , 2014, Tissue barriers.

[58]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[59]  A. Shvarts,et al.  Lack of lymphangiogenesis during breast carcinogenesis , 2004, Journal of Clinical Pathology.

[60]  Dai Fukumura,et al.  Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization. , 2007, Microvascular research.

[61]  Shiladitya Sengupta,et al.  Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system , 2005, Nature.

[62]  Robert Gray,et al.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. , 2006, The New England journal of medicine.

[63]  Rakesh K. Jain,et al.  Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.

[64]  Dai Fukumura,et al.  Benefits of vascular normalization are dose and time dependent--letter. , 2013, Cancer research.

[65]  R K Jain,et al.  Transport of molecules in the tumor interstitium: a review. , 1987, Cancer research.

[66]  M. Sefidgar,et al.  Numerical modeling of drug delivery in a dynamic solid tumor microvasculature. , 2015, Microvascular research.

[67]  M Kardar,et al.  Dynamics of tumor growth and combination of anti-angiogenic and cytotoxic therapies , 2007, Physics in medicine and biology.

[68]  Quan Long,et al.  Study of tumor blood perfusion and its variation due to vascular normalization by anti-angiogenic therapy based on 3D angiogenic microvasculature. , 2009, Journal of biomechanics.

[69]  M. Stockler,et al.  Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  R K Jain,et al.  Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. , 1992, Cancer research.

[71]  R. Jain.  Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[72]  M. Dewhirst,et al.  Effect of Pazopanib on Tumor Microenvironment and Liposome Delivery , 2010, Molecular Cancer Therapeutics.